Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell)
- Development stage
- Phase 2
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell) is a multivalent vaccine candidate developed by Sinovac (specifically Sinovac Dalian and Sinovac Biotech) for the prevention of rotavirus gastroenteritis in infants. The vaccine is produced using Vero cell technology and contains six reassortant rotavirus strains, designed to provide broad protection against the most prevalent rotavirus serotypes (typically G1, G2, G3, G4, G8, and G9). It is currently in Phase II clinical development in China, where it is being evaluated for safety and immunogenicity in healthy infants aged 6–12 weeks, often in comparison to licensed pentavalent vaccines like Lerduo.
- Other names
- oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell)hexavalent reassortant rotavirus vaccineSinovac hexavalent rotavirus vaccineoral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell)
02
Targets
VP4 (Rotavirus VP4)VP7 (Rotavirus A Outer Capsid Glycoprotein VP7)RVA (Rotavirus A)
Beyond the preview
Go deeper on oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell).